Using CD11b-Agonists to Make Pancreatic Cancer Treatable with Immunotherapy
Project 1: Employing CD11b-Agonists to Render PDAC Responsive to Immunotherapy
This study is exploring a new way to boost the effectiveness of immunotherapy for pancreatic cancer by using a special drug called GB1275 to help your immune cells work better, and it’s for patients who are looking for improved treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10916342 on NIH RePORTER |
What this research studies
This research investigates a new approach to enhance the effectiveness of immunotherapy for pancreatic ductal adenocarcinoma (PDAC), a type of cancer that has shown resistance to current treatments. The team aims to reprogram immune cells within the tumor environment using a novel drug called GB1275, which targets CD11b. By combining this treatment with existing therapies like Gemcitabine, Abraxane, and PD-1 blockade, the researchers hope to improve patient outcomes. The study will also identify biomarkers that can predict how well patients respond to this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic pancreatic ductal adenocarcinoma who have not responded to standard immunotherapy.
Not a fit: Patients with non-metastatic pancreatic cancer or those who have already had extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment options and outcomes for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results with similar approaches in reprogramming immune cells to enhance cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Denardo, David G — Washington University
- Study coordinator: Denardo, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.